Back to top
more

Eton Pharmaceuticals (ETON)

(Delayed Data from NSDQ)

$8.35 USD

8.35
89,552

-0.27 (-3.13%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $8.36 +0.01 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer

by Zacks Equity Research

Following the approval, Merck's (MRK) Keytruda is the first immunotherapy approved in the EU for first-line treatment for HER2-positive advanced gastric cancer in adults whose tumors express PD-L1.

Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals

by Zacks Equity Research

Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.

UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why

by Zacks Equity Research

This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the candidate is expected next year.

Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%

by Zacks Equity Research

Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.

Eton Pharmaceuticals, Inc. (ETON) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Eton Pharmaceuticals, Inc. (ETON) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 300% and 84.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Meets Q4 Earnings Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 0% and 1.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 28.57% and 15.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Reports Break-Even Earnings for Q1

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of -100% and 19.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 300% and 6.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -56.94% and 85.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Patterson Cos. (PDCO) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Patterson Cos. (PDCO) delivered earnings and revenue surprises of 3.33% and 1.15%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -196.88% and 7.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 180% and 6.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Lilly (LLY) Beats on Q4 Earnings, Lags on Sales, Raises '23 View

by Zacks Equity Research

Eli Lilly's (LLY) earnings surpass fourth-quarter estimates while sales slightly miss the mark. The company raises its EPS guidance for 2023.

Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why

by Zacks Equity Research

Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.

Best Momentum Stocks to Buy for January 25th

by Zacks Equity Research

ETON, OKTA and VZLA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 25, 2023.

New Strong Buy Stocks for January 25th

by Zacks Equity Research

YEXT, CXM, ETON, OKTA, VZLA have been added to the Zacks Rank #1 (Strong Buy) List on January 25, 2023.

Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.

Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%

by Zacks Equity Research

Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.

Amarin Corporation (AMRN) Down 13% in One Week: Here's Why

by Zacks Equity Research

Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.

Best Momentum Stocks to Buy for January 23rd

by Zacks Equity Research

ETON, KMTUY and AU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 23, 2023.

New Strong Buy Stocks for January 23rd

by Zacks Equity Research

GFI, AU, ETON, KMTUY and STLA have been added to the Zacks Rank #1 (Strong Buy) List on January 23, 2023.

ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection

by Zacks Equity Research

Eton (ETON) gains as the its new drug application (NDA) for dehydrated alcohol injection for methanol poisoning is accepted for review by the FDA.